首页> 外文期刊>Human Reproduction >Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study
【24h】

Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study

机译:柠檬酸克罗米芬和地塞米松治疗耐克罗米芬的多囊卵巢综合征:一项前瞻性安慰剂对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The aim of this work was to evaluate the efficacy of adding dexamethazone (DEX) (high dose, short course) to clomiphene citrate (CC) in CC-resistant polycystic ovary syndrome (PCOS) with normal dehydroepiandrosterone sulphate (DHEAS) in induction of ovulation. METHODS: Eighty infertile women with CC-resistant PCOS were randomly assigned into two groups. Group I: Clomiphene citrate 100 mg/day was given from day 3 to day 7 of the cycle and DEX 2 mg/day from day 3 to day 12 of the cycle. Group II: Same protocol of CC combined with placebo (folic acid tablets) was given from day 3 to day 12 of the cycle. The main outcome was ovulation. Secondary measures included number of follicles >18 mm endometrial thickness and pregnancy rate. Ovarian follicular response was monitored by transvaginal ultrasound. HCG 10 000 U was given when at least one follicle measured 18 mm, and timed intercourse was advised. RESULTS: There were no statistically significant differences between groups as regards age, duration of infertility, BMI, waist–hip ratio (WHR), menstrual pattern, hirsutism, serum DHEAS or day of HCG administration. The mean number of follicles >18 mm at the time of HCG administration and the mean endometrial thickness were significantly higher in the DEX group than in the placebo group (P < 0.05). Similarly, there were significantly higher rates of ovulation (75 versus 15%) (P < 0.001) and pregnancy (40 versus 5%) (P < 0.05) in the DEX group. Dexamethazone was very well tolerated as no patients complained of any side effect. There was a significant difference between the responders and non-responders in the presence of oligomenorrhea, amenorrhea or hirsutism. CONCLUSION: Induction of ovulation by adding DEX (high dose, short course) to CC in CC-resistant PCOS with normal DHEAS is associated with no adverse anti-estrogenic effect on the endometrium and higher ovulation and pregnancy rates in a significant number of patients. Induction with DEX appears to be independent on age, period of infertility, BMI or WHR.
机译:背景:这项工作的目的是评估在正常的硫酸脱氢表雄酮硫酸盐(DHEAS)诱导下,对CC耐药的多囊卵巢综合征(PCOS)中向地氯米芬(CC)中添加地塞米松(DEX)(大剂量,短疗程)的疗效排卵期方法:将80例CC抵抗型PCOS不育妇女随机分为两组。组I:从周期的第3天至第7天给予柠檬酸氯米芬100mg /天,从周期的第3天至第12天给予DEX 2mg /天。组II:从周期的第3天到第12天,给予相同的CC与安慰剂(叶酸片)联合治疗方案。主要结局是排卵。次要措施包括> 18 mm子宫内膜厚度的卵泡数目和妊娠率。通过阴道超声监测卵巢的卵泡反应。当至少一个卵泡的直径为18 mm时,给予HCG 10000 U,并建议定时性交。结果:两组之间在年龄,不孕持续时间,BMI,腰臀比(WHR),月经方式,多毛症,血清DHEAS或HCG给药日方面无统计学差异。给予HCG时,DEX组的平均卵泡数> 18 mm和平均子宫内膜厚度显着高于安慰剂组(P <0.05)。同样,DEX组的排卵率显着更高(75%对15%)(P <0.001)和妊娠(40%对5%)(P <0.05)。地塞米松的耐受性非常好,因为没有患者抱怨有任何副作用。在有少经,闭经或多毛症的情况下,有反应者和无反应者之间存在显着差异。结论:在具有正常DHEAS且对CC耐药的PCOS中,通过在CC中添加DEX(高剂量,短疗程)诱导排卵,与对子宫内膜无不利的抗雌激素作用以及许多患者较高的排卵和妊娠率有关。 DEX的诱导似乎与年龄,不孕期,BMI或WHR无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号